CRISPR-Cas9 Gene Therapy Shows Promise in Preclinical Angelman Study
News
A CRISPR-Cas9-based gene therapy designed to increase the production of ubiquitin protein ligase E3A (UBE3A) — the enzyme lacking in Angelman syndrome — partially or completely corrected physical and behavioral deficits in a mouse ... Read more